Inotiv, Inc. (NOTV)
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
$48.24M
Mr. Robert W. Leasure Jr.
2,099.00
West Lafayette, IN
Nov 25, 1997
-0.48
$-3.84
0.03
0.31
-19.80%
-0.47
-0.00
0.25
0.09
0.19
-12.81%
-43.49%
Similar stocks (6)
Sotera Health Company
SHC
Sera Prognostics, Inc.
SERA
FONAR Corporation
FONR
Exagen Inc.
XGN
Neuronetics, Inc.
STIM
DarioHealth Corp.
DRIO
ETF Exposure (14)
iShares Micro-Cap ETF
IWC
0.00823%
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
0.003%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Quantitative Funds - Vanguard Growth and Income Fund
VGIAX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Growth and Income Fund
VQNPX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (6)
Sotera Health Company
SHC
Sera Prognostics, Inc.
SERA
FONAR Corporation
FONR
Exagen Inc.
XGN
Neuronetics, Inc.
STIM
DarioHealth Corp.
DRIO
ETF Exposure (14)
iShares Micro-Cap ETF
IWC
0.00823%
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
0.003%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Quantitative Funds - Vanguard Growth and Income Fund
VGIAX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Growth and Income Fund
VQNPX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%